Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients

S. D'Atri, D. Piccioni, A. Castellano, V. Tuorto, A. Franchi, N. Christiansen, S. Frankel, Y. M. Rustum, G. Papa, F. Mandeli, E. Bonmassar

Research output: Contribution to journalArticle

Abstract

Background: A clinical pilot study performed by our group showed that dacarbazine can induce a marked reduction of blast cells in patients with acute myelogenous leukaemia (AML). Leukaemic blasts (LB) from responsive patients showed low levels of O6-allcylguanine-DNA alkyltransferase (OGAT). Design: An in vitro study was performed to evaluate OGAT levels and sensitivity to temozolomide (a triazene compound that spontaneously decomposes into the active metabolite of dacarbazine) in a relatively large number of LB samples. Results: OGAT levels varied widely among the LB of different patients, with a mean value higher in acute lymphoblastic leukaemias than in AML. About 25% of LB obtained from patients with AML showed low OGAT activity, in the range corresponding to that observed in leukaemic patients responsive to dacarbazine in vivo. A reasonable inverse correlation was found between OGAT levels and LB sensitivity to temozolomide. Conclusions: Triazenes could have a therapeutic potential in human leukaemias. Moreover, OGAT determination could provide rapid and reliable information about a patient's susceptibility to these antitumor agents.

Original languageEnglish
Pages (from-to)389-393
Number of pages5
JournalAnnals of Oncology
Volume6
Issue number4
Publication statusPublished - 1995

Fingerprint

Triazenes
Blast
Leukemia
DNA
temozolomide
Acute
Dacarbazine
Acute Myeloid Leukemia
Metabolites
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mean Value
Antineoplastic Agents
Susceptibility
DNA alkyltransferase
Decompose
Evaluate
Cell

Keywords

  • Alkyltransferase
  • Chemosensitivity
  • Leukaemia
  • Triazenes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology

Cite this

D'Atri, S., Piccioni, D., Castellano, A., Tuorto, V., Franchi, A., Christiansen, N., ... Bonmassar, E. (1995). Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients. Annals of Oncology, 6(4), 389-393.

Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels : Studies with blasts of leukaemic patients. / D'Atri, S.; Piccioni, D.; Castellano, A.; Tuorto, V.; Franchi, A.; Christiansen, N.; Frankel, S.; Rustum, Y. M.; Papa, G.; Mandeli, F.; Bonmassar, E.

In: Annals of Oncology, Vol. 6, No. 4, 1995, p. 389-393.

Research output: Contribution to journalArticle

D'Atri, S, Piccioni, D, Castellano, A, Tuorto, V, Franchi, A, Christiansen, N, Frankel, S, Rustum, YM, Papa, G, Mandeli, F & Bonmassar, E 1995, 'Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients', Annals of Oncology, vol. 6, no. 4, pp. 389-393.
D'Atri, S. ; Piccioni, D. ; Castellano, A. ; Tuorto, V. ; Franchi, A. ; Christiansen, N. ; Frankel, S. ; Rustum, Y. M. ; Papa, G. ; Mandeli, F. ; Bonmassar, E. / Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels : Studies with blasts of leukaemic patients. In: Annals of Oncology. 1995 ; Vol. 6, No. 4. pp. 389-393.
@article{1606044df1b04d68ac298696f782f653,
title = "Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients",
abstract = "Background: A clinical pilot study performed by our group showed that dacarbazine can induce a marked reduction of blast cells in patients with acute myelogenous leukaemia (AML). Leukaemic blasts (LB) from responsive patients showed low levels of O6-allcylguanine-DNA alkyltransferase (OGAT). Design: An in vitro study was performed to evaluate OGAT levels and sensitivity to temozolomide (a triazene compound that spontaneously decomposes into the active metabolite of dacarbazine) in a relatively large number of LB samples. Results: OGAT levels varied widely among the LB of different patients, with a mean value higher in acute lymphoblastic leukaemias than in AML. About 25{\%} of LB obtained from patients with AML showed low OGAT activity, in the range corresponding to that observed in leukaemic patients responsive to dacarbazine in vivo. A reasonable inverse correlation was found between OGAT levels and LB sensitivity to temozolomide. Conclusions: Triazenes could have a therapeutic potential in human leukaemias. Moreover, OGAT determination could provide rapid and reliable information about a patient's susceptibility to these antitumor agents.",
keywords = "Alkyltransferase, Chemosensitivity, Leukaemia, Triazenes",
author = "S. D'Atri and D. Piccioni and A. Castellano and V. Tuorto and A. Franchi and N. Christiansen and S. Frankel and Rustum, {Y. M.} and G. Papa and F. Mandeli and E. Bonmassar",
year = "1995",
language = "English",
volume = "6",
pages = "389--393",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels

T2 - Studies with blasts of leukaemic patients

AU - D'Atri, S.

AU - Piccioni, D.

AU - Castellano, A.

AU - Tuorto, V.

AU - Franchi, A.

AU - Christiansen, N.

AU - Frankel, S.

AU - Rustum, Y. M.

AU - Papa, G.

AU - Mandeli, F.

AU - Bonmassar, E.

PY - 1995

Y1 - 1995

N2 - Background: A clinical pilot study performed by our group showed that dacarbazine can induce a marked reduction of blast cells in patients with acute myelogenous leukaemia (AML). Leukaemic blasts (LB) from responsive patients showed low levels of O6-allcylguanine-DNA alkyltransferase (OGAT). Design: An in vitro study was performed to evaluate OGAT levels and sensitivity to temozolomide (a triazene compound that spontaneously decomposes into the active metabolite of dacarbazine) in a relatively large number of LB samples. Results: OGAT levels varied widely among the LB of different patients, with a mean value higher in acute lymphoblastic leukaemias than in AML. About 25% of LB obtained from patients with AML showed low OGAT activity, in the range corresponding to that observed in leukaemic patients responsive to dacarbazine in vivo. A reasonable inverse correlation was found between OGAT levels and LB sensitivity to temozolomide. Conclusions: Triazenes could have a therapeutic potential in human leukaemias. Moreover, OGAT determination could provide rapid and reliable information about a patient's susceptibility to these antitumor agents.

AB - Background: A clinical pilot study performed by our group showed that dacarbazine can induce a marked reduction of blast cells in patients with acute myelogenous leukaemia (AML). Leukaemic blasts (LB) from responsive patients showed low levels of O6-allcylguanine-DNA alkyltransferase (OGAT). Design: An in vitro study was performed to evaluate OGAT levels and sensitivity to temozolomide (a triazene compound that spontaneously decomposes into the active metabolite of dacarbazine) in a relatively large number of LB samples. Results: OGAT levels varied widely among the LB of different patients, with a mean value higher in acute lymphoblastic leukaemias than in AML. About 25% of LB obtained from patients with AML showed low OGAT activity, in the range corresponding to that observed in leukaemic patients responsive to dacarbazine in vivo. A reasonable inverse correlation was found between OGAT levels and LB sensitivity to temozolomide. Conclusions: Triazenes could have a therapeutic potential in human leukaemias. Moreover, OGAT determination could provide rapid and reliable information about a patient's susceptibility to these antitumor agents.

KW - Alkyltransferase

KW - Chemosensitivity

KW - Leukaemia

KW - Triazenes

UR - http://www.scopus.com/inward/record.url?scp=0028986307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028986307&partnerID=8YFLogxK

M3 - Article

C2 - 7619755

AN - SCOPUS:0028986307

VL - 6

SP - 389

EP - 393

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

ER -